Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y4W2
UPID:
LAS1L_HUMAN
Alternative names:
Protein LAS1 homolog
Alternative UPACC:
Q9Y4W2; A9X410; Q5JXQ0; Q8TEN5; Q9H9V5
Background:
Ribosomal biogenesis protein LAS1L, also known as Protein LAS1 homolog, plays a crucial role in the biogenesis of the 60S ribosomal subunit, essential for protein synthesis. It is pivotal in the maturation of the 28S rRNA and operates as part of the 5FMC complex, influencing gene transactivation through desumoylation processes.
Therapeutic significance:
The protein's involvement in Intellectual developmental disorder, X-linked, syndromic, Wilson-Turner type, underscores its therapeutic significance. Understanding the role of Ribosomal biogenesis protein LAS1L could open doors to potential therapeutic strategies for this neurologic disorder, offering hope for targeted interventions.